The human body harbors a complex ecosystem of interconnected life forms. In fact, only half of the cells of the human body are actually human. The other half are the tiny microscopic organisms, including bacteria, fungi, and viruses, collectively referred to as the Human Microbiome. We now appreciate that the genetic information encoded by this diverse community of microbes dramatically expands on the core metabolic and functional potential of the human genome.
Importantly, a majority of the human microbiome resides within the intestinal tract, which is also hometo an array of key components of the human immune system. Due to their proximity, the microbiome is in constant communication with the body’s immune system. Through both its expanded metabolic activities and interaction with the immune system, the microbiome represents an untapped treasure trove for novel therapies and diagnostics.
we can use the developing gut microbiome of infants to help us understand the keystone species that drive healthy development
Ecological theory dictates that the first organisms to colonize a pristine environment, known as founder species, control the development of environmental conditions and influence future accumulation of biodiversity. With this ecosystems approach in mind, Siolta Therapeutics leverages data on the developing infant gut microbiome to help us understand the microbes and conditions that drive healthy human gut microbiome development. We use these data to understand how early-life disturbances to the gut microbiome lead to increased susceptibility to future disease. More importantly, our platform helps us develop and test novel microbiome-based therapeutics to treat and prevent disease at its origin in the gut.